Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 7/20 | 0.58 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.43 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.43 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.43 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.43 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | RICTOR | Q6R327 | 1/20 | 0.42 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.42 |
| ▸ | MAPKAP1 | Q9BPZ7 | 1/20 | 0.42 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15312950 | 1.00 | SCN9A (0.58) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL17169499 | 1.00 | SCN9A (0.58) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL2304747 | 0.92 | SCN9A (0.58) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL385128 | 0.92 | SCN9A (0.58) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL3326929 | 0.92 | SCN9A (0.58) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL3335162 | 0.89 | SCN9A (0.56) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL2305169 | 0.88 | SCN9A (0.57) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL3327213 | 0.84 | SCN9A (0.51) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL3327217 | 0.84 | SCN9A (0.51) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL280726 | 0.84 | SCN9A (0.59) | SCN9AMTORRICTORRPTORMAPKAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2789617-B1 | Method of preparation of Enantiomers of spiro-oxindole compounds | XENON PHARMACEUTICALS INC (CA) | 2016-08-17 | — | — | EP | claimed |
| EP-2789617-A1 | Method of preparation of Enantiomers of spiro-oxindole compounds | Xenon Pharmaceuticals Inc. (CA) | 2014-10-15 | — | — | EP | claimed |
| EP-1888595-B1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2012-02-01 | — | — | EP | claimed |
| US-7700641-B2 | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2010-04-20 | — | — | US | claimed |
| US-20060252812-A1 | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2006-11-09 | — | — | US | claimed |
| EP-3266444-A1 | PHARMACEUTICAL COMPOSITIONS OF SPIRO-OXINDOLE COMPOUND FOR TOPICAL ADMINISTRATION AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2018-01-10 | — | — | EP | disclosed |
| EP-3241834-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2017-11-08 | — | — | EP | disclosed |
| EP-3241834-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2017-11-08 | — | — | EP | disclosed |
| EP-2538919-B1 | PHARMACEUTICAL COMPOSITIONS OF SPIRO-OXINDOLE COMPOUND FOR TOPICAL ADMINISTRATION AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2017-07-12 | — | — | EP | disclosed |
| US-9695185-B2 | Synthetic methods for spiro-oxindole compounds | XENON PHARMACEUTICALS INC. (CA) | 2017-07-04 | — | — | US | disclosed |
| US-9695185-B2 | Synthetic methods for spiro-oxindole compounds | XENON PHARMACEUTICALS INC. (CA) | 2017-07-04 | — | — | US | disclosed |
| US-9695185-B2 | Synthetic methods for spiro-oxindole compounds | XENON PHARMACEUTICALS INC. (CA) | 2017-07-04 | — | — | US | disclosed |
| US-20100099728-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-04-22 | — | — | US | disclosed |
| US-7700641-B2 | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2010-04-20 | — | — | US | disclosed |
| US-7700641-B2 | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2010-04-20 | — | — | US | disclosed |
| US-7700641-B2 | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2010-04-20 | — | — | US | disclosed |
| WO-2008046087-A2 | SPIRO COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-04-17 | — | — | WO | disclosed |
| EP-1888595-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-02-20 | — | — | EP | disclosed |
| US-20060252812-A1 | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2006-11-09 | — | — | US | disclosed |
| WO-2006110917-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252812-A1 | Spiro-oxindole compounds and their uses as therapeutic agents | OPRK1, OPRD1, SCN3A | SCN9A 47/4885SCN7A 79/4885SCN5A 61/4885 |
| US-20100099728-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV3, TRPV1, TRPC3 | SCN9A 61/4885SCN7A 72/4885SCN5A 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.